Vertex : CHMP Grants Positive Opinion For KAFTRIO - KALYDECO In People Ages 12 And Older With CF

Vertex Pharmaceuticals Inc. (VRTX) said that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP adopted a positive opinion for KAFTRIO in a combination regimen with KALYDECO or ivacaftor 150 mg to treat people with cystic fibrosis or CF ages 12 and older with one F508del mutation and one minimal function mutation or two F508del mutations in the cystic fibrosis transmembrane conductance regulator or CFTR gene.